齐多夫定立即治疗可保护感染猿猴免疫缺陷病毒的新生猕猴免于艾滋病的快速发作。
Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.
作者信息
Van Rompay K K, Otsyula M G, Marthas M L, Miller C J, McChesney M B, Pedersen N C
机构信息
California Regional Primate Research Center, University of California, Davis 95616.
出版信息
Antimicrob Agents Chemother. 1995 Jan;39(1):125-31. doi: 10.1128/AAC.39.1.125.
Abstract
Simian immunodeficiency virus (SIV) infection of newborn rhesus macaques is a practical animal model of pediatric AIDS. Intravenous inoculation of rhesus newborns with uncloned SIVmac resulted in a high virus load, no antiviral immune responses, severe immunodeficiency, and a high mortality rate within 3 months. In contrast, immediate oral zidovudine (AZT) treatment of SIV-inoculated rhesus newborns either prevented infection or resulted in reduced virus load, enhanced antiviral immune responses, a low frequency of AZT-resistant virus isolates, and delayed disease progression with negligible toxicity. These results suggest that early chronic AZT treatment of human immunodeficiency virus-exposed newborns may have benefits that outweigh its potential side effects.
摘要
新生恒河猴感染猿猴免疫缺陷病毒（SIV）是儿童艾滋病的一种实用动物模型。给恒河猴新生儿静脉接种未克隆的SIVmac会导致高病毒载量、无抗病毒免疫反应、严重免疫缺陷以及在3个月内出现高死亡率。相比之下，对接种SIV的恒河猴新生儿立即进行口服齐多夫定（AZT）治疗，要么可预防感染，要么可降低病毒载量、增强抗病毒免疫反应、降低AZT耐药病毒分离株的出现频率，并延缓疾病进展，且毒性可忽略不计。这些结果表明，对暴露于人类免疫缺陷病毒的新生儿进行早期长期AZT治疗可能利大于弊。
相似文献
1
Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.齐多夫定立即治疗可保护感染猿猴免疫缺陷病毒的新生猕猴免于艾滋病的快速发作。
Antimicrob Agents Chemother. 1995 Jan;39(1):125-31. doi: 10.1128/AAC.39.1.125.
2
Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques.病毒因素决定了感染猿猴免疫缺陷病毒的新生恒河猴向艾滋病的进展。
J Virol. 1995 Jul;69(7):4198-205. doi: 10.1128/JVI.69.7.4198-4205.1995.
3
Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection.对怀孕猕猴进行疫苗接种可保护新生猕猴免受黏膜型猿猴免疫缺陷病毒感染。
J Infect Dis. 1996 Jun;173(6):1327-35. doi: 10.1093/infdis/173.6.1327.
4
Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.以恒河猴婴儿感染猿猴免疫缺陷病毒（SIV）作为模型来测试抗逆转录病毒药物预防和治疗效果：口服3'-叠氮-3'-脱氧胸苷可预防SIV感染。
Antimicrob Agents Chemother. 1992 Nov;36(11):2381-6. doi: 10.1128/AAC.36.11.2381.
5
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.给予9-[2-(膦酰甲氧基)丙基]腺嘌呤（PMPA）预防恒河猴围产期猿猴免疫缺陷病毒感染。
AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):761-73. doi: 10.1089/aid.1998.14.761.
6
Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection.新生恒河猴的被动免疫可预防口腔感染猿猴免疫缺陷病毒。
J Infect Dis. 1998 May;177(5):1247-59. doi: 10.1086/515270.
7
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.两剂替诺福韦酯可保护新生猕猴免受口服猿猴免疫缺陷病毒感染。
AIDS. 1998 Jun 18;12(9):F79-83. doi: 10.1097/00002030-199809000-00001.
8
9
Zidovudine treatment prolongs survival and decreases virus load in the central nervous system of rhesus macaques infected perinatally with simian immunodeficiency virus.齐多夫定治疗可延长围产期感染猴免疫缺陷病毒的恒河猴的生存期，并降低其中枢神经系统中的病毒载量。
J Infect Dis. 1995 Jul;172(1):59-69. doi: 10.1093/infdis/172.1.59.
10
Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques.
J Med Primatol. 1994 Feb-May;23(2-3):175-83. doi: 10.1111/j.1600-0684.1994.tb00119.x.
引用本文的文献
1
Nonhuman primate models of pediatric viral diseases.儿科病毒性疾病的非人灵长类动物模型。
Front Cell Infect Microbiol. 2024 Dec 3;14:1493885. doi: 10.3389/fcimb.2024.1493885. eCollection 2024.
2
Tackling HIV and AIDS: contributions by non-human primate models.应对艾滋病毒和艾滋病：非人类灵长类动物模型的贡献。
Lab Anim (NY). 2017 May 22;46(6):259-270. doi: 10.1038/laban.1279.
3
Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?小鼠与猴子：动物模型能否用于研究儿童HIV-1感染的神经学后果？
ACS Chem Neurosci. 2015 Aug 19;6(8):1276-89. doi: 10.1021/acschemneuro.5b00044. Epub 2015 Jun 19.
4
A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential.抗人类免疫缺陷病毒 1 型药物对猴免疫缺陷病毒感染的抗病毒活性的定量测定：剂量反应曲线斜率强烈影响类特异性抑制潜能。
J Virol. 2012 Oct;86(20):11368-72. doi: 10.1128/JVI.01563-12. Epub 2012 Aug 8.
5
Italian consensus statement on paediatric HIV infection.意大利关于儿科 HIV 感染的共识声明。
Infection. 2010 Aug;38(4):301-19. doi: 10.1007/s15010-010-0020-5. Epub 2010 Jun 1.
6
Evaluation and treatment of the human immunodeficiency virus-1-exposed infant.人类免疫缺陷病毒1型暴露婴儿的评估与治疗
Paediatr Child Health. 2004 Jul;9(6):409-28. doi: 10.1093/pch/9.6.409.
7
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.在慢性RT-SHIV感染的恒河猴长期接受替诺福韦单药治疗期间，逆转录酶中具有K70E和K65R突变的病毒突变体的相继出现及其临床意义。
Retrovirology. 2007 Apr 6;4:25. doi: 10.1186/1742-4690-4-25.
8
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.对感染猿猴免疫缺陷病毒的新生猕猴采用替诺福韦单一疗法进行结构化治疗中断。
J Virol. 2006 Jul;80(13):6399-410. doi: 10.1128/JVI.02308-05.
9
Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.在感染了含有来自1型人类免疫缺陷病毒逆转录酶的重组猿猴免疫缺陷病毒的恒河猴中，通过高效抗逆转录病毒疗法抑制病毒载量。
J Virol. 2005 Jun;79(12):7349-54. doi: 10.1128/JVI.79.12.7349-7354.2005.
10
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.在替诺福韦治疗期间，CD8 + 细胞介导的对毒性猿猴免疫缺陷病毒的抑制作用。
J Virol. 2004 May;78(10):5324-37. doi: 10.1128/jvi.78.10.5324-5337.2004.
本文引用的文献
1
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.用于测定临床1型人类免疫缺陷病毒分离株药物敏感性的标准化外周血单核细胞培养试验。RV - 43研究组，艾滋病临床试验组病毒学委员会耐药性工作组。
Antimicrob Agents Chemother. 1993 May;37(5):1095-101. doi: 10.1128/AAC.37.5.1095.
2
Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection.1型人类免疫缺陷病毒垂直感染中的早期病毒血症和免疫反应。
J Infect Dis. 1993 May;167(5):1008-13. doi: 10.1093/infdis/167.5.1008.
3
Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants.HIV-1感染婴儿体内抗人类免疫缺陷病毒（HIV）抗体产生的个体发生情况。
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2340-4. doi: 10.1073/pnas.90.6.2340.
4
Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response.在原发性HIV-1感染期间给予齐多夫定可能与免疫反应不那么强烈有关。
AIDS. 1993 Jan;7(1):127-8. doi: 10.1097/00002030-199301000-00020.
5
Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.对出生时暴露于人类免疫缺陷病毒的婴儿给予齐多夫定的I期评估。
J Pediatr. 1993 Jan;122(1):137-44. doi: 10.1016/s0022-3476(05)83507-3.
6
High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.接受抗逆转录病毒治疗的儿童体内的人类免疫缺陷病毒对齐多夫定产生高水平耐药，但对扎西他滨或去羟肌苷未产生耐药。
J Pediatr. 1993 Jul;123(1):9-16. doi: 10.1016/s0022-3476(05)81530-6.
7
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.人类免疫缺陷病毒临床分离株对抗逆转录病毒药物的耐药性。
Antimicrob Agents Chemother. 1993 Jun;37(6):1207-13. doi: 10.1128/AAC.37.6.1207.
8
The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group.齐多夫定在妊娠晚期感染人类免疫缺陷病毒的孕妇及其婴儿中的药代动力学和安全性：I期获得性免疫缺陷综合征临床试验组研究（方案082）。齐多夫定协作工作组
Am J Obstet Gynecol. 1993 May;168(5):1510-6. doi: 10.1016/s0002-9378(11)90791-1.
9
Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children.
J Immunol. 1993 Apr 15;150(8 Pt 1):3569-81.
10
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.齐多夫定治疗降低母婴1型人类免疫缺陷病毒传播。儿童艾滋病临床试验组方案076研究小组。
N Engl J Med. 1994 Nov 3;331(18):1173-80. doi: 10.1056/NEJM199411033311801.
Zotero 插件